高横向分辨率光声显微成像解析结直肠癌肝转移灌注异质性
本研究开发了一种光声显微成像方法,在结直肠癌肝转移小鼠模型中依据微血管结构区分血管生成型和血管共选择型转移。PAM所示血管参数与组织病理学验证一致,血管共选择型对贝伐珠单抗治疗不敏感,血管生成型治疗后血管密度显著下降。
要点
- PAM可区分结直肠癌肝转移的血管生成型与血管共选择型微血管结构。
- 血管共选择型转移对贝伐珠单抗治疗具有耐药性。
- 血管密度、血管连接点密度、血管直径和腔隙度是分型的关键参数。
核心结论
- PAM可量化微血管特征,区分结直肠癌肝转移的血供模式。
- 血管共选择型转移被证实对贝伐珠单抗治疗耐药。
研究设计与样本
- 模型通过脾内注射HCT116-luc或HT29-luc细胞建立。
- 采用光声显微成像观察肝转移灶血管结构,并以组织病理学分析验证诊断准确性。
- 组间PAM参数差异采用单因素方差分析或独立样本t检验评估。
关键影像表现/征象
- 血管生成型转移的血管密度低于血管共选择型(15.66%±4.38 vs 31.44%±6.95;P<.001)。
- 血管生成型转移的血管连接点密度低于血管共选择型(1.19×10⁻³ n/px²±0.52 vs 3.12×10⁻³ n/px²±1.11;P=.001)。
- 血管生成型转移的血管直径大于血管共选择型(31.45 µm±4.59 vs 13.68 µm±1.61;P<.001)。
- 血管生成型转移的腔隙度高于血管共选择型(0.294 au±0.095 vs 0.148 au±0.059;P=.003)。
- 上述血管结构差异在8周进展期内持续存在。
诊断标准与关键数值
- 血管生成型诊断参数:血管密度15.66%±4.38,血管连接点密度1.19×10⁻³ n/px²±0.52,血管直径31.45 µm±4.59,腔隙度0.294 au±0.095。
- 血管共选择型诊断参数:血管密度31.44%±6.95,血管连接点密度3.12×10⁻³ n/px²±1.11,血管直径13.68 µm±1.61,腔隙度0.148 au±0.059。
- 贝伐珠单抗治疗3周后血管生成型转移血管密度下降33.3%(未治疗15.66%±4.38 vs 治疗10.44%±4.91;P=.047)。
- 贝伐珠单抗治疗3周后血管共选择型转移血管密度无显著差异(未治疗31.44%±6.95 vs 治疗28.82%±3.56;P=.56)。
临床应用与阅片要点
- PAM血管结构分型可为结直肠癌肝转移抗血管生成治疗决策提供参考。
- 识别血管共选择型转移有助于预判贝伐珠单抗治疗无效。
- 血管密度、直径和腔隙度为PAM分型的核心可量化指标。
局限性
- 研究为动物模型实验,临床转化效能尚需验证。
- PAM成像深度有限,应用于深部肝转移灶可能受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To develop a photoacoustic microscopy (PAM) method for classifying colorectal liver metastasis (CRLM) microvascular networks as angiogenesis-type or vessel co-option-type at different metastatic stages and to evaluate their responses to bevacizumab. Materials and Methods Seventy-two BALB/c nude mice received intrasplenic injections of HCT116-luc or HT29-luc cells to establish CRLM models. PAM was used to visualize CRLM vascular architecture, and its diagnostic accuracy was validated through histopathologic analysis. Intergroup differences in PAM parameters were assessed with one-way analysis of variance or independent-samples t tests. Results PAM differentiated angiogenesis-type from vessel-co-option-type CRLMs according to distinct vascular architectures: Angiogenesis-type CRLMs exhibited lower vessel density (15.66% ± 4.38 vs 31.44% ± 6.95; P < .001) and vessel junction density (1.19 × 10-3 n/px2 ± 0.52 vs 3.12 × 10-3 n/px2 ± 1.11; P = .001) and higher vessel diameter (31.45 µm ± 4.59 vs 13.68 µm ± 1.61; P < .001) and lacunarity (0.294 arbitrary units [au] ± 0.095 vs 0.148 au ± 0.059; P = .003) than vessel co-option-type CRLMs. These differences persisted throughout the 8-week progression period. A 33.3% reduction in vessel density at 3 weeks following bevacizumab treatment was observed in angiogenesis-type CRLMs (untreated, 15.66% ± 4.38 vs treated at 3 weeks, 10.44% ± 4.91; P = .047), with no evidence of a difference in vessel co-option-type CRLMs (untreated, 31.44% ± 6.95 vs treated at 3 weeks, 28.82% ± 3.56; P = .56). Conclusion PAM quantified microvascular signatures differentiating CRLM blood supply patterns and identified vessel co-option-type metastases as resistant to bevacizumab. Keywords: Angiogenesis, Bevacizumab, Colorectal Cancer, Histopathologic Growth Pattern, Liver Metastases, Photoacoustic Imaging, Photoacoustic Microscopy, Vessel Co-Option Supplemental material is available for this article. © RSNA, 2026 See also editorial by Wang and Chen in this issue.
引用
- Wang, Xie, Wu, et al. Deciphering Colorectal Liver Metastasis Perfusion Heterogeneity: Identification of Distinct Vascular Phenotypes through High-Lateral-Resolution Photoacoustic Microscopy. Radiol Imaging Cancer. 2026. PMID: 42429583. doi:10.1148/rycan.250523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。